XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Guide Acquisition - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Feb. 23, 2021
Mar. 31, 2021
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Business Acquisition [Line Items]          
Value of shares issued for upfront payment of acquisition   $ 120,032      
Research and development expense     $ 154,953    
Contingent consideration liabilities       $ 31,910 $ 31,367
Common Stock          
Business Acquisition [Line Items]          
Value of shares issued for upfront payment of acquisition   $ 10      
Guide Therapeutics, Inc. | Merger Agreement          
Business Acquisition [Line Items]          
Business Acquisition, merger agreement date Feb. 23, 2021        
Business combination upfront consideration paid in common stock $ 120,000        
Value of shares issued for upfront payment of acquisition 120,000        
Research and development expense 155,000        
Contingent consideration liabilities $ 36,500        
Guide Therapeutics, Inc. | Merger Agreement | Common Stock          
Business Acquisition [Line Items]          
Number of shares issued for upfront payment of acquisition 1,087,153        
Guide Therapeutics, Inc. | Merger Agreement | Technology Milestones | Maximum | Former Stockholders and Optionholders          
Business Acquisition [Line Items]          
Potential milestone payable in form of common stock $ 100,000        
Guide Therapeutics, Inc. | Merger Agreement | Product Milestones | Maximum | Former Stockholders and Optionholders          
Business Acquisition [Line Items]          
Potential milestone payable in form of common stock $ 220,000